XLRN Acceleron Pharma Inc.

50.28
+0.36  (+1%)
Previous Close 49.92
Open 49.92
Price To Book 5.74
Market Cap 2,668,954,412
Shares 53,081,830
Volume 43,075
Short Ratio
Av. Daily Volume 368,971
Stock charts supplied by TradingView

NewsSee all news

  1. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  2. Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting

    Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called

  3. Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay

  4. Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)

    Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug

  5. Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 1Q 2020.
Sotatercept - PULSAR
Pulmonary arterial hypertension (PAH)
Phase 3 trial initiated - noted October 30, 2018.
Luspatercept - COMMANDS
First-line, lower-risk Myelodysplastic syndromes (MDS)
Phase 2 data at ASH December 2019 noted primary endpoint met in 10%~32% of patients across four cohorts.
Luspatercept
Myelofibrosis
Phase 2 data due 1Q 2020.
ACE-083
Charcot-Marie-Tooth disease (CMT)
PDUFA date April 4, 2020. Advisory Committee meeting originally set for December 18, 2019 is no longer required - noted December 6, 2019.
Luspatercept
Myelodysplastic syndromes (MDS) cancer
Phase 2 data did not achieve statistically significant improvements in functional endpoints relative to placebo - September 16, 2019.
ACE-083
Facioscapulohumeral muscular dystrophy
Phase 2 data released June 12, 2017 - primary endpoint not met.
Dalantercept - DART Study
Renal Cell Carcinoma (RCC) - cancer
Phase 2 updated data at ASCO June 2018. 55% achieved a clinically meaningful erythroid improvement.
Luspatercept Extension Study - PACE-MDS
Myelodysplastic Syndromes
Announced April 4, 2019 intention to discontinue development.
ACE-2494
Healthy volunteers
Phase 2 data due YE 2020.
Luspatercept - BEYOND
Non-transfusion-dependent beta-thalassemia
FDA Approval announced November 8, 2019.
Luspatercept
Beta-thalassemia
Phase 2 exploratory trial data due 2020.
Sotatercept - SPECTRA
Pulmonary arterial hypertension (PAH)

Latest News

  1. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  2. Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting

    Initial results from phase 2 study evaluating an investigational use of luspatercept-aamt in myelofibrosis-associated anemia showed promising clinical activity – companies plan to initiate pivotal, phase 3 study called

  3. Acceleron Appoints Jay T. Backstrom, M.D., M.P.H., to Newly Created Role as Head of Research and Development

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Jay

  4. Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt)

    Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that following the late-cycle review meeting on December 4, 2019, they were notified by the U.S. Food and Drug

  5. Acceleron Appoints Global Innovation and Drug Development Executive Kemal Malik, MB BS, to its Board of Directors

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today the appointment of Kemal

  6. Acceleron Named a "Most Honored" Company in Institutional Investor 2020 "All-America Executive Team" Rankings

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, announced today that it has been

  7. Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes

    Bristol-Myers Squibb Company (NYSE:BMY) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee will hold a review of Bristol-Myers

  8. Acceleron to Host Conference Call and Webcast to Review Data Presented at the 61st American Society of Hematology Annual Meeting

    Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, December 10, 2019 at 6:00 a.m. EST to review highlights from its presentations at the 61st American Society of

  9. FDA Approves REBLOZYL® (luspatercept-aamt) for the Treatment of Anemia in Adults With Beta Thalassemia Who Require Regular Red Blood Cell Transfusions

    REBLOZYL is the first and only FDA-approved erythroid maturation agent, representing a new class of therapy for these patients Approval of REBLOZYL marks the first FDA-approved treatment for anemia in beta

  10. Acceleron Announces Luspatercept Presentations at the 61st American Society of Hematology Annual Meeting

    – Updated results from MEDALIST Phase 3 trial show 47.1% of patients with anemia associated with myelodysplastic syndromes treated with luspatercept achieved red blood cell transfusion independence for ≥ 8 weeks and

  11. Acceleron Reports Third Quarter 2019 Operating and Financial Results

    - FDA's review of luspatercept BLA for the beta-thalassemia and lower-risk MDS indications remains ongoing - - Six clinical abstracts accepted for presentation at the 61st American Society of Hematology (ASH) Annual

  12. Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Facioscapulohumeral Muscular Dystrophy

    – ACE-083 did not achieve statistically significant improvements in functional endpoints relative to placebo – – Acceleron to discontinue development of ACE-083 in facioscapulohumeral muscular dystrophy – – Topline

  13. Acceleron Receives FDA Orphan Drug Designation for Sotatercept in Pulmonary Arterial Hypertension

    Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the United States